Ootsuka Youichirou, Blessing William W
Department of Human Physiology, Centre for Neuroscience, School of Medicine, Flinders University, Bedford Park, SA 5042, Australia.
Neurosci Lett. 2006 Mar 6;395(2):170-4. doi: 10.1016/j.neulet.2005.10.062. Epub 2005 Nov 15.
Body temperature is decreased by 5-hydroxytryptamine 1A (5-HT1A) agonists and increased by 5-HT2A agonists. The present study determined whether changes in interscapular brown adipose tissue (iBAT) thermogenesis contribute to these effects in conscious unrestrained animals. Male Sprague-Dawley rats were pre-instrumented for measurement of iBAT and core temperature and tail artery blood flow one week before experiments. In the first series of experiments, rats were transferred from warm (25-28 degrees C) to cold (5-10 degrees C) environments. This increased iBAT temperature (+1.3 +/- 0.2 degrees C, P<0.01, n = 7) and reduced tail artery flow. Injection of the 5-HT1A agonist, 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin, 0.5 mg/kg, s.c.) reversed the increase in iBAT thermogenesis (-1.5 +/- 0.4 degrees C, P<0.01, n = 6), and decreased core temperature (-1.5 +/- 0.4 degrees C, P<0.01, n = 6). Pre-treatment with WAY-100635 (N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide trihydrochloride), a 5-HT1A antagonist, prevented effects of 8-OH-DPAT. In the second series of experiments, injection of a 5-HT2A agonist, DOI (R(-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride, 0.1 mg/kg, s.c.) increased both iBAT (+1.9 +/- 0.1 degrees C, P<0.01, n = 7) and core temperatures (+1.4+/-0.2 degrees C, P<0.01, n=7), and decreased tail artery blood flow. Subsequent injection of SR 46349B (trans-4-((3Z)3-[(2-dimethylaminoethyl)oxyimino]-3-(2-fluorophenyl) propen-1-yl)-phenol, hemifumarate, 0.5 mg/kg, s.c.), a 5-HT2A antagonist, reduced all these changes. Results indicate that activation of 5-HT1A receptors reduces sympathetic outflow to BAT and that activation of 5-HT2A receptors increases this outflow. Changes in core temperature mediated by brain/spinal pathways regulated by 5-HT1A and 5-HT2A receptors reflect coordinated changes in BAT-mediated heat production as well as changes in heat dissipation via the thermoregulatory cutaneous vascular beds.
5-羟色胺1A(5-HT1A)激动剂可降低体温,而5-HT2A激动剂则可升高体温。本研究确定了肩胛间棕色脂肪组织(iBAT)产热的变化是否有助于在清醒不受约束的动物中产生这些效应。雄性Sprague-Dawley大鼠在实验前一周预先安装仪器以测量iBAT、核心体温和尾动脉血流量。在第一系列实验中,将大鼠从温暖(25-28摄氏度)环境转移至寒冷(5-10摄氏度)环境。这使得iBAT温度升高(+1.3±0.2摄氏度,P<0.01,n = 7)并降低了尾动脉血流量。注射5-HT1A激动剂8-OH-DPAT(8-羟基-2-(二正丙基氨基)四氢萘,0.5mg/kg,皮下注射)可逆转iBAT产热的增加(-1.5±0.4摄氏度,P<0.01,n = 6),并降低核心体温(-1.5±0.4摄氏度,P<0.01,n = 6)。用5-HT1A拮抗剂WAY-100635(N-[2-[4-(2-甲氧基苯基)-1-哌嗪基]乙基]-N-(2-吡啶基)环己烷甲酰胺三盐酸盐)预处理可防止8-OH-DPAT的作用。在第二系列实验中,注射5-HT2A激动剂DOI(R(-)-1-(2,5-二甲氧基-4-碘苯基)-2-氨基丙烷盐酸盐,0.1mg/kg,皮下注射)可使iBAT(+1.9±0.1摄氏度,P<0.01,n = 7)和核心体温均升高(+1.4±0.2摄氏度,P<0.01,n = 7),并降低尾动脉血流量。随后注射5-HT2A拮抗剂SR 46349B(反式-4-((3Z)3-[(2-二甲氨基乙基)氧基亚氨基]-3-(2-氟苯基)丙烯-1-基)-苯酚,半富马酸盐,0.5mg/kg,皮下注射)可减少所有这些变化。结果表明,5-HT1A受体的激活减少了对BAT的交感神经输出,而5-HT2A受体的激活增加了这种输出。由5-HT1A和5-HT2A受体调节的脑/脊髓途径介导的核心体温变化反映了BAT介导的产热的协调变化以及通过体温调节性皮肤血管床的散热变化。